JP2023540206A5 - - Google Patents
Info
- Publication number
- JP2023540206A5 JP2023540206A5 JP2023512718A JP2023512718A JP2023540206A5 JP 2023540206 A5 JP2023540206 A5 JP 2023540206A5 JP 2023512718 A JP2023512718 A JP 2023512718A JP 2023512718 A JP2023512718 A JP 2023512718A JP 2023540206 A5 JP2023540206 A5 JP 2023540206A5
- Authority
- JP
- Japan
- Prior art keywords
- lymphoma
- pharmaceutical composition
- composition according
- anticancer agent
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063070984P | 2020-08-27 | 2020-08-27 | |
| US63/070,984 | 2020-08-27 | ||
| PCT/US2021/047778 WO2022047051A1 (en) | 2020-08-27 | 2021-08-26 | Use of a dhodh inhibitor compound in combination cancer therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023540206A JP2023540206A (ja) | 2023-09-22 |
| JP2023540206A5 true JP2023540206A5 (https=) | 2024-09-02 |
| JP7734742B2 JP7734742B2 (ja) | 2025-09-05 |
Family
ID=78000775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023512718A Active JP7734742B2 (ja) | 2020-08-27 | 2021-08-26 | 癌併用療法におけるｄｈｏｄｈ阻害剤化合物の利用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230285365A1 (https=) |
| EP (1) | EP4203950B1 (https=) |
| JP (1) | JP7734742B2 (https=) |
| KR (1) | KR20230078997A (https=) |
| CN (1) | CN116847874A (https=) |
| BR (1) | BR112023003493A2 (https=) |
| CA (1) | CA3190511A1 (https=) |
| ES (1) | ES3063941T3 (https=) |
| WO (1) | WO2022047051A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20211462T1 (hr) | 2017-04-24 | 2021-12-24 | Aurigene Discovery Technologies Limited | Postupci uporabe za trisupstituirane derivate benzotriazola kao inhibitora dihidroorotatne oksigenaze |
| TWI818954B (zh) | 2018-02-20 | 2023-10-21 | 法商施維雅藥廠 | 三取代之苯并三唑衍生物的使用方法 |
| JOP20210147A1 (ar) * | 2018-12-21 | 2023-01-30 | Les Laboratoires Servier Sas | صور بلورية وملح من مركب عضوي وتركيبات صيدلانية منه |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS57962B1 (sr) | 2013-02-25 | 2019-01-31 | Aurigene Discovery Tech Ltd | Derivati trisupstituisanog benzotriazola kao inhibitori dihidroorotat oksigenaze |
| US9603927B2 (en) * | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US20180369206A1 (en) * | 2017-04-24 | 2018-12-27 | Aurigene Discovery Technologies Limited | Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors |
| HRP20211462T1 (hr) * | 2017-04-24 | 2021-12-24 | Aurigene Discovery Technologies Limited | Postupci uporabe za trisupstituirane derivate benzotriazola kao inhibitora dihidroorotatne oksigenaze |
| TWI818954B (zh) | 2018-02-20 | 2023-10-21 | 法商施維雅藥廠 | 三取代之苯并三唑衍生物的使用方法 |
| WO2020109625A1 (en) * | 2018-11-30 | 2020-06-04 | Fondazione Centro San Raffaele | Combined treatment of primary central nervous system lymphoma |
| JOP20210147A1 (ar) | 2018-12-21 | 2023-01-30 | Les Laboratoires Servier Sas | صور بلورية وملح من مركب عضوي وتركيبات صيدلانية منه |
-
2021
- 2021-08-26 ES ES21783084T patent/ES3063941T3/es active Active
- 2021-08-26 CA CA3190511A patent/CA3190511A1/en active Pending
- 2021-08-26 EP EP21783084.3A patent/EP4203950B1/en active Active
- 2021-08-26 US US18/015,396 patent/US20230285365A1/en active Pending
- 2021-08-26 BR BR112023003493A patent/BR112023003493A2/pt unknown
- 2021-08-26 CN CN202180052749.9A patent/CN116847874A/zh active Pending
- 2021-08-26 WO PCT/US2021/047778 patent/WO2022047051A1/en not_active Ceased
- 2021-08-26 KR KR1020237004006A patent/KR20230078997A/ko active Pending
- 2021-08-26 JP JP2023512718A patent/JP7734742B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023540206A5 (https=) | ||
| CN105367482B (zh) | N‑酰基磺酰胺凋亡促进剂 | |
| JP2009502743A5 (https=) | ||
| JP2017518334A5 (https=) | ||
| JP2006501176A5 (https=) | ||
| JP2005537854A5 (https=) | ||
| CN108350016B (zh) | 抗病毒四氢呋喃衍生物 | |
| US20190263802A1 (en) | Compounds and method of use | |
| JP2021530444A5 (https=) | ||
| JP2006507265A5 (https=) | ||
| JP2014511840A5 (https=) | ||
| JP2022516974A5 (https=) | ||
| JP2006504766A5 (https=) | ||
| JP2017537969A5 (https=) | ||
| JP2008505157A5 (https=) | ||
| JP2022538817A5 (https=) | ||
| JP2023548190A5 (https=) | ||
| JP2024520630A5 (https=) | ||
| JP2007502832A5 (https=) | ||
| AU2017205749A1 (en) | Use of quinoline derivatives for treating oesophageal cancer and treatment method, pharmaceutical composition and kit thereof | |
| JP2024542984A5 (https=) | ||
| JP2018527360A5 (https=) | ||
| JP2024538730A5 (https=) | ||
| JP2022535609A5 (https=) | ||
| JP2025118775A5 (https=) |